



May 31, 2013

Gene Techno Science Co., Ltd.  
Code: 4584 (TSE Mothers)  
President  
Masanari Kawaminami

### **Standard Drug Price Listing and Start of Sales for Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF) in Japan**

Recombinant human granulocyte colony-stimulating factor (rhG-CSF, development code GBS-001) was today added to the National Health Insurance's Drug Price List in Japan. Fuji Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. started sales the same day. Gene Techno Science Co., Ltd. started the joint development of this filgrastim biosimilar with Fuji Pharma and clinical trials were conducted in Japan with Fuji Pharma and Mochida Pharmaceutical. On November 21, 2012, Fuji Pharma and Mochida Pharmaceutical received approval from the Ministry of Health, Labour and Welfare to manufacture and sell rhG-CSF in Japan.

rhG-CSF stimulates the differentiation and proliferation of neutrophilic precursor cells into neutrophils, mobilizes the peripheral blood progenitor cells (PBPC), and activates the function of mature neutrophils. As a result, one indication for rhG-CSF is for increasing the number of neutrophils when neutrophils decline due to chemotherapy or after a bone marrow transplant.

#### **Media Contact**

Eisaku Nakamura  
Business Development Dept.  
Tel: (81)-3-3517-1353  
E-mail : info\_ir@g-gts.com